Sales of AbbVie’s Humira (adalimumab) reached $4.4 billion for Europe at the end of June this year, according to healthcare data firm IQVIA. This represents a huge opportunity for companies ...
This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the US in January.
Objectives We present a series of QAs for Humira® (adalimumab) from >500 drug substance batches produced from 4 facilities and 5 production scales from 2001-2013. Humira is approved for 10 indications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback